The latest Association of the British Pharmaceutical Industry medical representatives' examination results show that 75% of the 1,100 medical representatives who sat this in 2007 achieved a pass in the assessment, now in its 30th year.
"For 30 years, the ABPI exam has ensured that UK medical representatives demonstrate their essential knowledge of medicines and their effect upon the human body, giving health care professionals confidence that industry representatives are well-trained by their companies," said Ian Irving, the ABPI's director of examinations.
More than 8,000 medical representatives are currently employed in the UK. The exam must be passed by all within the first two years of their employment. Since 2005, 4,700 students have taken the examination. Results have remained constant, with 75% achieving a first-time pass and 99% passing on second sitting. Students must achieve a score of at least 60% in each paper in order to pass. The qualification procedure was established in 1969 to improve the overall quality of medical representation. It ensures students have a good knowledge of the industry and Code of Practice; the human body, pathology and pharmacology; and body systems. Students can gain a distinction grade by scoring 80% or more in all six exam subjects, with one in five students achieving this.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze